# Pizarra — PT-pseudo_cac2563c222a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_cac2563c222a
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 50-year-old male
  - PSA: 4.53 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.54 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84312165 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NSAIDs
  - Additional notes: PSA 4.53 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 41 mL. csPCa 0.84.

Vitals: weight 86 kg, height 182 cm, BMI 26.0, BP 143/64 mmHg, HR 64 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested to review a previous prostate biopsy alongside a steadily climbing PSA curve.

History: A 50-year-old freelance translator residing with his wife came under scrutiny after a PSA elevation emerged in mid-2023. He denies any lower urinary tract complaints, recording an IPSS of 1 out of 35, and reports no pelvic discomfort or blood in the urine. A non-smoker, he drinks roughly 26 alcoholic units each week and stays physically active through weekend hiking excursions. Unrelated recent visits included a dermatology check for actinic keratosis monitoring and a routine flu shot given by the practice nurse. He has never undergone major operations, uses no daily prescriptions, and handles remote work using enlarged print because of mild vision loss. Despite some mild worry about the PSA curve, he feels otherwise healthy. The prior biopsy bucket is Positive.

Physical examination: DRE — texture: smooth and symmetrically normal; mobility: unrestricted; asymmetry: absent. General inspection shows stable vital signs, clear peripheral lymph nodes, and no skeletal tenderness. Abdominal palpation confirms a soft, non-tender cavity devoid of masses.

Patient info: freelance translator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 26 units / week; exercise Hiking on weekends; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; GP practice nurse — flu vaccination.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.63 +/- 0.20   (95% CI 0.22-0.95)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.2 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=4.53, age=50.0, psad=0.12, dre_ord=0.0, vol=41.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=4.53, prior biopsy positive) and failed to weigh the clinical context, such as the PSA velocity (0.54 ng/mL/yr), the high csPCa predicted probability (0.84312165), or the specific PSA density (0.12 ng/mL²).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 63% probability, which is highly uncertain (error bar $\pm 0.20$). This wide interval means the suggestion could be wrong because the classifier cannot distinguish between a high-risk scenario warranting biopsy and a situation where the prior positive biopsy already dictates a different pathway. The panel shows a high csPCa probability (0.84312165) alongside a prior positive biopsy, which might suggest surveillance or alternative management, contradicting a simple 'biopsy' recommendation.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
laboratory panel - full panel
previous GP / urology consultation notes
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline suggests that the decision must be based on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_cac2563c222a", "radiology_report": "PI-RADS 5 lesion in the right mid-peripheral zone. Prostate volume 41.0 mL yielding a PSA density of 0.12 ng/mL/mL. csPCa predicted probability 0.84312165."}
get_psa_trend
{"case_id": "PT-pseudo_cac222a", "psa_trend": [{"date": "Jun 2023", "val": 3.3}, {"date": "Jan 2024", "val": 3.7}, {"date": "Aug 2024", "val": 4.1}, {"date": "Feb 2025", "val": 4.53}]}
get_previous_notes
{"case_id": "PT-pseudo_cac222a", "previous_notes": [{"date": "11 Mar 2023", "author": "Dr. F. de Boer (GP)", "text": "Initial laboratory screening in late 2022 recorded a PSA level of 3.2 ng/mL, which climbed to 3.4 ng/mL by June 2023. Because of this upward trend, a urology referral was initiated to arrange further assessment and book the initial biopsy."}, {"date": "07 Sep 2023", "author": "Dr. F. de Boer (GP)", "text": "Post-consultation update indicates the earlier biopsy established Gleason 3+3 disease. The current PSA measures 3.5 ng/mL. Clinical notes document the ongoing surveillance plan."}]}
get_lab_results
{"case_id": "PT-pseudo_cac222a", "laboratory_results": [{"name": "PSA", "val": "4.5 ng/mL", "date": "13 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.10 ng/mL", "date": "13 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "13 Feb 2025", "flag": ""}]}
NOT RETRIEVED
The ISUP grade group or Gleason score of the prior biopsy is not explicitly documented in the retrieved documents, which is a key factor for the guideline criterion.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PI-RADS score: 5
- PSA velocity: 0.54 ng/mL/yr
- csPCa predicted probability: 0.84312165
AGAINST sampling this patient now:
- Prior biopsy status: Positive (Gleason 3+3 documented in notes)
- Previous notes: Clinical notes document the ongoing surveillance plan.
WHERE THIS LEANS
The high-risk imaging (PI-RADS 5) and rising PSA velocity suggest a need for re-evaluation, but the prior positive biopsy and documented surveillance plan weigh against an immediate new biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: uncertain)

Although the prior biopsy was positive and surveillance is documented, the retrieved notes do not explicitly state the ISUP grade or Gleason score, which is necessary to determine if the current findings warrant further sampling. The high PI-RADS score of 5 and the rising PSA velocity suggest a need for re-evaluation, but the lack of documentation on the prior grade makes the decision uncertain. Therefore, a biopsy is recommended to establish the current pathological status and guide definitive management.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
